

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/597,803
	Filing Date	April 13, 2007
	First Named Inventor	Robert Tridgett
	Group Art Unit	1628
	Examiner Name	Craig Ricci
Sheet 1 of 4		Attorney Docket No: 3063.002US1

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-20050064034A1	3/24/2005	Li, Boyong, et al.	6/16/2004
	US-20080319000A1	12/25/2008	Tridgett, Robert	8/11/2008
	US-20090275605A1	11/5/2009	Duffield, A. J., et al.	8/4/2006
	US-20100055133A1	3/4/2010	Duffield, A. J., et al.	8/12/2009
	US-20100087475A1	4/8/2010	Duffield, A. J., et al.	9/8/2009
	US-20110053866A1	3/3/2011	Duffield, A., et al.	8/12/2010

FOREIGN PATENT DOCUMENTS				
Examiner Initial *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T 1
	GB-2410947A	8/17/2005	Tridgett, Robert, et al.	
	GB-2463452A	3/17/2010	Duffield, Andrew John	
	WO-2006069030A1	6/29/2006	Rariy, Roman, et al.	
	WO-2008079404A2	7/3/2008	Nangia, Avinash, et al.	
	WO-2009150474A1	12/17/2009	Grayson, Ben, et al.	
	WO-2011019956A2	2/17/2011	Duffield, A. J., et al.	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.", Cell, 72(6), [No authors listed], (Mar. 26, 1993), 971-83	
	"Application Serial No. 12/555,695, 312 Amendment filed 11-16-10", 8 pgs	
	"Application Serial No. 12/555,695, Notice of Allowance mailed 01-06-11", 7 pgs	
	"Application Serial No. 12/555,695, Notice of Allowance mailed 10-08-10", 8 pgs	
	"Application Serial No. 12/997,258, Preliminary Amendment filed 12-10-10", 5 pgs	
	"International Application Serial No. PCTGB2009051013, International Search Report and Written Opinion mailed 10-08-10", 14 pgs	
	ABRAHAMSSON, BERTIL, et al., "Absorption, Gastrointestinal Transit, and Tablet Erosion of Felodipine Extended-Release (ER) Tablets", Pharmaceutical Research 10(5), (1993), 709-714	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/597,803
	Filing Date	April 13, 2007
	First Named Inventor	Robert Tridgett
	Group Art Unit	1628
	Examiner Name	Craig Ricci
Sheet 2 of 4		Attorney Docket No: 3063.002US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	APARICIO-LEGARZA, IRAIDE M, et al., "Deficits of [3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia", Neurosci Lett., 232(1), (Aug. 22, 1997), 13-6	
	BENJAMIN, C. M, et al., "Proceed with care: direct predictive testing for Huntington disease.", Am J Hum Genet., 55(4), (Oct., 1994), 606-17	
	BENNETT, FRANK C, et al., "An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice", J Pharmacol Exp Ther., 280(2), (Feb., 1997), 988-1000	
	BERTHOIS, Y., et al., "SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo", Br J Cancer., 88(3), (Feb. 10, 2003), 438-46	
	BEVAN, S, et al., "Development of a Competitive Antagonist for the Sensory Neurone Excitant Capsaicin", British Journal of Pharmacology: Proceedings Supplement, [Online]. Retrieved from the Internet: <URL: http://www.papA2online.org/vol_12issue4-abst077P.html >, (Dec., 1990), 23 pgs	
	BONHAUS, D. W, et al., "The pharmacology and distribution of human 5-hydroxytryptamine _{2B} (5-HT _{2B}) receptor gene products: comparison with 5-HT _{2A} and 5-HT _{2C} receptors.", Br J Pharmacol., 115(4), (Jun., 1995), 622-8	
	BRENT, P. J, et al., "Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture.", Eur J Pharmacol., 278(2), (May 15, 1995), 151-60	
	BRINKMAN, R R, et al., "The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size", Am J Hum Genet., 60(5), (May, 1997), 1202-10	
	BROWN, C. M, et al., "Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain.", Br J Pharmacol., 99(4), (Apr., 1990), 803-9	
	COLORCON LIMITED, "The Effect of In-Vitro Dissolution Parameters on the Release Rate of a Low Dose, Low Solubility Drug from Extended Release Hypromellose Matrix Formulations", Poster Reprint, Controlled Release Society, (July 2006), 4 pgs.	
	CRAWFORD, K. W, et al., "Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines", Cancer Res., 62(1), (Jan. 1, 2002), 313-22	
	ERICKSON, J. D, et al., "Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.", Proc Natl Acad Sci U S A., 93(10), (May 14, 1996), 5166-71	
	GANAPATHY, MALLIGA E, et al., "Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line", J Pharmacol Exp Ther., 289(1), (Apr., 1999), 251-60	
	GRAYSON, B, et al., "The Effect of PCP on Novel Object Recognition in the Rat", Journal of Psychopharmacology Vol. 18, No. 3, Supplement, (2004), A55	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/597,803
	Filing Date	April 13, 2007
	First Named Inventor	Robert Tridgett
	Group Art Unit	1628
	Examiner Name	Craig Ricci
Sheet 3 of 4		Attorney Docket No: 3063.002US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	GRAYSON, B., et al., "Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.", Behav Brain Res., 184(1), (Nov. 22, 2007), 31-8	
	GU, H., et al., "Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence", J Biol Chem., 269(10), (Ma. 11, 1994), 7124-30	
	HALLORAN, MARGARET M, et al., "Cellular adhesion molecules in rat adjuvant arthritis.", Arthritis Rheum., 39(5), (May, 1996), 810-9	
	HANNER, MARKUS, et al., "Purification, molecular cloning, and expression of the mammalian sigma1-binding site", Proc Natl Acad Sci U S A., 93(15), (Jul. 23, 1996), 8072-7	
	HASHIMOTO, KENJI, et al., "Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain.", European Journal of Pharmacology, 236(1), (May 12, 1993), 159-163	
	HENSIEK, A. E, et al., "Relevance of new psychotropic drugs for the neurologist", J Neurol Neurosurg Psychiatry, 72(3), (Mar., 2002), 281-5	
	HUTTUNEN, MATTI, et al., "The evolution of the serotonin-dopamine antagonist concept", J Clin Psychopharmacol., 15(1 Suppl 1), (Feb., 1995), 4S-10S	
	IDRIS, N F, et al., "The ability of antipsychotics to prevent a subchronic PCP-induced cognitive deficit in the novel object recognition task in the rat", Neuroscience 2005 Abstract: Presentation Number 67.15, (2005), 1 pg	
	JENTSCH, DAVID J, et al., "The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.", Neuropsychopharmacology, 20(3), (Mar., 1999), 201-25	
	KARPUJ, MARCELA V, et al., "Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.", Nat Med., 8(2), (Feb., 2002), 143-9	
	KNOERZER, DEBBIE BARNEY, et al., "Clinical and histological assessment of collagen-induced arthritis progression in the diabetes-resistant BB/Wor rat", Toxicol Pathol., 25(1), (Jan-Feb, 1997), 13-9	
	MELTZER, HERBERT, "The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics", J Clin Psychopharmacol., 15(1 Suppl 1), (Feb., 1995), 2S-3S	
	MILLAN, M. J, et al., "Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization", Pharmacol Biochem Behav., 71(4), (Apr., 2002), 589-98	
	MOSHAROV, EUGENE V, et al., "Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells", J Neurosci., 23(13), (Jul. 2, 2003), 5835-45	
	NEAR, JOSEPH, et al., "[3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles.", Mol Pharmacol., 30(3), (Sep., 1986), 252-7	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/597,803
	Filing Date	April 13, 2007
	First Named Inventor	Robert Tridgett
	Group Art Unit	1628
	Examiner Name	Craig Ricci
Sheet 4 of 4		Attorney Docket No: 3063.002US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	NOCIARI, M, et al., "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity", Journal of Immunological Methods 213(2), (Jun 1998), 157-167	
	OPPENHEIMER-MARKS, N, et al., "Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo.", J Clin Invest., 101(6), (Mar. 15, 1998), 1261-72	
	SCHERMAN, DANIEL, et al., "[3H]dihydrotrabenazine, a new in vitro monoaminergic probe for human brain", J Neurochem., 50(4), (Apr., 1998), 1131-6	
	SCHIMMER, RALPH C, et al., "Streptococcal cell wall-induced arthritis: requirements for IL-4, IL-10, IFN-gamma, and monocyte chemoattractant protein-1", J Immunol., 160(3), (Feb. 1, 1998), 1466-71	
	SPRUCE, BARBARA A, et al., "Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.", Cancer Res., 64(14), (Jul. 15, 2004), 4875-86	
	STAAL, R. G, et al., "In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.", J Pharmacol Exp Ther., 293(2), (May, 2000), 329-35	
	SUTCLIFFE, J S, et al., "A preliminary investigation into the effects of gender on cognitive performance in the rat using the novel object recognition task", Endocrine Abstracts, 10, Presented at the 196th meeting of the Society for Endocrinology, (2005), P50	
	UHLEN, S., et al., "The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.", J Pharmacol Exp Ther., 271(3), (Dec., 1994), 1558-65	
	UHLEN, STAFFAN, "[3H]RS79948-197 binding to human, rat, guinea pig and pig a2A-, a2B- and a2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine", European Journal of Pharmacology 343(1), (1998), 93-101	
	WANG, B., et al., "Expression of sigma 1 receptor in human breast cancer", Breast Cancer Res Treat., 87(3), (Oct., 2004), 205-14	
	WINGSTRAND, KARIN, et al., "Bioavailability from felodipine extended-release tablets with different dissolution properties", International Journal of Pharmaceutics 60, (1990), 151-156	
	ZUCKER, M., et al., "Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter", Life Sci., 69(19), (Sep. 28, 2001), 2311-7	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached